Literature DB >> 32962861

Development of bis-ANS-based modified fluorescence titration assay for IFIT/RNA studies.

Anna Dobieżyńska1, Joanna Miszkiewicz2, Zbigniew M Darżynkiewicz1, Michał Tyras2, Anna Stankiewicz-Drogoń1, Joanna Trylska1, Edward Darżynkiewicz3, Renata Grzela4.   

Abstract

The interferon-induced proteins with tetratricopeptide repeats (IFITs) are a family of RNA-binding proteins that are very highly expressed during antiviral response of immune system. IFIT proteins recognize and tightly bind foreign RNA particles. These are primarily viral RNAs ended with triphosphate at the 5' or lacking methylation of the first cap-proximal nucleotide but also in vitro transcribed RNA synthesized in the laboratory. Recognition of RNA by IFIT proteins leads to the formation of stable RNA/IFIT complexes and translational shut off of non-self transcripts. Here, we present a fluorescent-based assay to study the interaction between RNA molecules and IFIT family proteins. We have particularly focused on two representatives of this family: IFIT1 and IFIT5. We found a probe that competitively with RNA binds the positively charged tunnel in these IFIT proteins. The use of this probe for IFIT titration allowed us to evaluate the differences in binding affinities of mRNAs with different variants of 5' ends.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Fluorescence probe; IFIT; Protein-RNA interaction; Titration assay

Year:  2020        PMID: 32962861     DOI: 10.1016/j.bbrc.2020.09.006

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  1 in total

1.  Transcriptome-Wide Analysis of Human Liver Reveals Age-Related Differences in the Expression of Select Functional Gene Clusters and Evidence for a PPP1R10-Governed 'Aging Cascade'.

Authors:  Thomas Schreiter; Robert K Gieseler; Ramiro Vílchez-Vargas; Ruy Jauregui; Jan-Peter Sowa; Susanne Klein-Scory; Ruth Broering; Roland S Croner; Jürgen W Treckmann; Alexander Link; Ali Canbay
Journal:  Pharmaceutics       Date:  2021-11-25       Impact factor: 6.321

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.